ArticleMolecular cancer therapeutics2013

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

John E Weldon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.